Project Grant K23HL179516
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $178K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $670,017 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define a regulatory pathway in type 2 innate lymphoid cells that prevents chronic allergic lung inflammation and airways hyperresponsiveness. The award funds research into the E3 ubiquitin ligase CUL5 and its role in restricting cytokine receptor signaling in ILC2s. Preliminary data...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $161,450 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund a three-year research career development program supporting Dr. Lyndsey Muehling's training as a Research Assistant Professor. Dr. Muehling will complete a rigorous computational biology curriculum, engage in grant writing courses and career development activities, and receive mentorship from an...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $161,935 to the University of Pittsburgh on September 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored clinical scientist research career development initiative. Under the direction of Dr. Kristina Gaietto, an instructor of pediatrics at Children's Hospital of Pittsburgh, this project will deliver research products focused on improving diagnostic...
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $245,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how sensory neuron release of substance P stimulates B cell immunoglobulin E production in asthma. The research will examine the mechanism by which the neuropeptide substance P, released from neurons sensitized during asthmatic...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $127,253 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate protein palmitoylation in asthma pathogenesis and treatment. Dr. Salamone will use cell and animal models to test the hypothesis that dysregulated protein palmitoylation modulates airway epithelial and T cell function. In the mentored K99 phase, she will evaluate palmitoylation in epithelial cells by...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $2,386,712 on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which endotoxin exposure protects against allergic asthma through MIZ1-mediated epigenetic regulation and to evaluate the therapeutic potential of targeting the MIZ1 pathway. The research will pursue three specific aims: investigation of how endotoxin downregulates MIZ1 and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a $169,020 Project Grant effective August 15, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This career development award supports a five-year research and training initiative focused on investigating the role of lymph node stromal cells in unicentric Castleman disease, a rare lymphoproliferative disorder. The award funds an...
- The National Heart, Lung, and Blood Institute awarded $777,498 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on multiscale integration of mucin secretion and ion transport rates in asthmatic mucus plug formation and persistence. The research tests the applicability of a biophysical paradigm called the "two-gel" paradigm to asthma pathogenesis, examining whether asthma mucus...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $189,000 to the University of Colorado-Denver on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a proof-of-principle study investigating environmental predictors of treatment responsiveness for pediatric acute asthma exacerbations. The research addresses the clinical challenge that treatment response to standard protocols for asthma exacerbations in...